The technology used to make the CBCA analytical standard was developed by Teewinot Life Sciences.
Teewinot CEO Jeffrey Korentur told us “researchers will be able to use the standard validate and confirm that the compound they are using either is, or is not, CBCA. Standards may have other uses in research and development including preliminary efficacy studies.”
He added that: “AMRI is licensed to use our technology to manufacture and sell the CBCA analytical standard.”
Teewinot has a suite of biosynthetic technologies it uses to make cannabinoid-based compounds in micro-organisms.
The idea is that the approach is faster and more consistent than plant-based production.
The agreement with AMRI is seperate to the deal Teewinot has with the US contractor to scale up the cannabinoid production process.
Korentur told us: “Our scale up is in progress now, and we anticipate being able to produce kilogram quantities of GMP manufactured cannabinoids by Q1 2017.”
News of the deal comes a week after Florida-based Teewinot licensed rights to its cannabinoid active pharmaceutical ingredient (API) manufacturing technology to Nemus Biosciences.
That agreement was signed days after Teewinot’s Ireland-based subsidiary, Full Spectrum Laboratories, was granted a US patent for the technology.